Mustang Bio gets FDA orphan drug designation for malignant glioma
Mustang Bio (NASDAQ:MBIO) and development partner, Nationwide Children’s Hospital (NCH), received FDA orphan drug designation for MB-108 for the treatment of malignant glioma.
Malignant glioma is a type of brain cancer with a median survival of less than 18 months. MB-108 is an oncolytic virus that has demonstrated direct anti-tumor activity and the reversal of tumor-associated immunosuppression in preclinical studies.
“MB-108 has demonstrated the potential to address an area of high unmet medical need, and we believe it is an important new treatment for patients with malignant glioma,” Dr. Martina Sersch, Mustang’s CMO, said in a statement.
Mustang and NCH are evaluating MB-108 for the treatment of recurrent glioblastoma multiforme in a Phase 1 trial at the University of Alabama at Birmingham.